PETALING JAYA: PMCK Bhd
is staying cautiously optimistic of its prospects, supported by steady demand for private healthcare services and stable patient flows across its core specialties.
Notwithstanding the conclusion of the Hospital Services Outsourcing Programme (HSOP) in December 2025, PMCK said it remains open to re-engaging with HSOP or similar public-private initiatives should such opportunities arise.
Releasing its results for its third quarter ended Jan 31 (3Q26) yesterday, PMCK posted a net profit of RM3.9mil on a revenue of RM22.7mil.
In its filing, PMCK said: “Healthcare support services continued to be the main contributor to the group’s revenue, while inpatient care remained the primary driver of patient care revenue.
“During the quarter, the group recorded a net gain on reversal of impairment of financial assets of RM3mil following the full settlement received in relation to previously undelivered Covid-19 vaccines.”
For the nine months ended January, PMCK registered a bottom line of RM10.6mil, with turnover coming in at RM69.9mil.
It said during this period, it incurred one-off listing expenses of RM2.67mil, which was offset by the total net gain on reversal of impairment of financial assets of RM6.1mil as mentioned above.
The group made its ACE Market debut on July 9 last year.
Compared to the quarter ended October 2025, PMCK said net profit and revenue were down 33.3% and 10.7% from RM5.8mil and RM25.4mil, respectively.
“The decline was primarily attributable to lower inpatient revenue arising from reduced inpatient volumes and a lower bed occupancy rate, following the conclusion of the HSOP in December 2025,” it explained.
PMCK had declared a dividend of 0.12 sen per share during 2Q26.
